



Ed and Ethel Moore Alzheimer's Disease Research Program

**FY 2014/2015 Funding Opportunity Announcement
Questions and Answers**

October 23, 2014

1. Should grants be consortia among different investigators or whether individuals can apply? Could you clarify?
Any researcher at a university or research institute in Florida is eligible to apply. Researchers may collaborate, but only one researcher may serve as the principal investigator. The Department will issue an Addendum to the Funding Opportunity Announcement ("FOA") to indicate that the Department intends to award grants to support research, not just research consortia.
2. After reviewing the highlights on page 6, I was unsure if the initial submission needed to be a consortia application or if individual researchers are allowed to submit their own grant app. If individual researchers are allowed to submit single applications, is there a limit to the number of researchers at a single institution.
There is not a limit to the number of researchers from a single institution that may apply. See the answer to Question 1. However, each researcher may only submit one application as the principal investigator for this FOA.
3. Is there a limit on submission per institution?
No.
4. What are going to be the restrictions on Board members regarding submitted proposals? Is being a PI or co-PI not allowed?
Board members are not allowed to be a principal investigator or receive any compensation from a Program grant award. See page 11 in the FOA. (D. Guidelines for Alzheimer's Disease Research Grant Advisory Board Member Participation)
5. Can single investigators apply, or are you specifically looking for consortium proposals? If single investigators can apply, what is the duration of an award?
See the answer to Question 1.
6. Should a brief description of our proposed research be included in the Letter of Intent (Ed and Ethel Moore Alzheimer's Disease Grant Program mechanism)?
No. The required fields are listed within the FOA.
7. Could you please tell me if there is a page limit on the grant application.
Limits are listed for each section of the application within the online application.

8. We are working on the Letter of Intent for the Ed and Ethel Moore Alzheimer's Disease Research Program. I would like to know if there is a template to follow.
There is no specific template or required format. See Section II, paragraph 3 the FOA, "Required Grant Application Components."
9. Would research on dietary supplements (nutraceuticals) qualify under the Pharmacotherapeutic Research opportunity for this request for proposals?
See Section I, paragraph 2 of the FOA for a description of qualifying research.
10. Would you please email me information about the page lengths of Research/Project Plan and Health Impact section of the Ed and Ethel Moore Alzheimer's Disease Research Program application.
The online application system specifies word limits for each section. It will be available no later than October 24, 2014.
11. Our organization would like to apply as the lead organization and we are an established research institute which makes us an eligible institution as per the definition on Pg. 18 of the Funding Announcement. Does our PI have to be a full-time faculty at our organization or can he/she be a full-time faculty at any eligible institution in Florida?
The PI must be faculty at the lead institution. The PI must be able to serve as a principal investigator (able to act on behalf of the applicant organization, for example to hire staff and expend funds).
12. In the situation of a consortium or contractual agreement (definition pg. 17), may our organization (an eligible institution) be the applicant lead institution and contract with another eligible institution for a full-time faculty member to serve as our PI?
See the answer to question 11.
13. The FOA allows up to 15% indirect costs? Will we be required to submit a negotiated indirect cost rate agreement or something similar with the budget?
The Department allows indirect costs up to 15%. Applicants will be expected to show their established indirect cost rate and what it is based on (i.e., salary, benefits, etc.).
14. In the FOA on page 40 it appears as if these are two year grants?
The grants will expire at the end of fiscal year 2014/2015 (June 30, 2015). The Attachment I that is shown on page 40 is an example form that will be modified in an addendum to more accurately reflect the timeframe of this funding opportunity.
15. I see that 2 years is listed in the budget section, but in other locations the announcement mentioned 5 years.
The two years listed in the budget section refers to a template that is provided as an example. Also, see answer to #14 above.
16. Could you please provide the maximum amount (i.e. 100 K? 300K or 500K/per year) and maximum duration (i.e. number of years) per application.
The FOA states that awards are anticipated to be between \$500,000 and \$1,000,000 and will end on June 30, 2015.
17. What is the duration of the award? Are they limited to one or two year or can a project be over 3 years or more?
Applicants should plan on projects to end on June 30, 2015.

18. I would like to confirm if there's an expected project period (3, 4, or 5 years) and any limitation on the total budget amount. The guideline is not clear on these items; it only references that "the budget must explain the planned spending."

Projects must end on June 30, 2015. Also see answers to questions 10, 15, and 16.

19. Please verify that the funds for these grants must be spent by Dec 2015. We were planning to enroll and follow-up participants in an aging study for up to 3 years, but that may not be feasible if the funds cannot be distributed over 3 years.

See answer to Questions 10, 17 and 18.

20. To determine the level of necessary details, we seek to know whether all reviewers have expertise in Alzheimer's disease. Further, would a list of review committee members be made public?

All reviewers will have the experience, training and education necessary to assess the scientific merit of applications as they relate to the prevention, diagnosis, treatment, and cure of Alzheimer's disease. The Department typically does not publish a list of review committee members for such funding opportunities.